A phase 1-2, open-label, dose-finding, proof of concept, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of CX-2009 in adults with metastatic or locally advanced unresectable solid tumors.
A phase III, open-label, randomized study to evaluate the efficacy and safety of adjuvant alectinib versus adjuvant platinum-based chemotherapy in patients with completely resected stage IB to stage IIIA anaplastic lymphoma kinase-positive NSCLC.
A randomized, phase III study of firstline immunotherapy alone or in combination with chemotherapy in induction/maintenance or postprogression in advanced nonsquamous non‐small cell lung cancer (NSCLC) with immunobiomarker signature‐driven analysis.
A randomized phase III trial for surgically resected early stage non-small cell lung cancer: Crizotinib versus observation for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein.
Phase II multi-center study of pembrolizumab in combination with platinum-based doublet chemotherapy in patients with EGFR mutation and ALK positive non-small cell lung cancer with progressive disease following prior tyrosine kinase inhibitors (TKIs).